1-8 of 8
Frederico Xavier
Close
Sort by
Journal Articles

May-Thurner Syndrome Should be Explored As a Possible Existing Risk Factor in Pediatric Patients Presenting with Non-Central Venous Line Associated Deep Vein Thrombosis

Erica Mamauag, Cynthia Liang, Katelin Magnan, Frederico Xavier
Journal: Blood
Blood (2023) 142 (Supplement 1): 1277.
https://doi.org/10.1182/blood-2023-178961
Published: 2023
Journal Articles

Post-Immune Tolerance Induction Prophylactic FVIII Infusions May Not be Necessary for Tolerized Hemophilia a Patients on Emicizumab

Pragya Singh, Erica Mamauag, Deirdre Nolfi-Donegan, Frederico Xavier
Journal: Blood
Blood (2023) 142 (Supplement 1): 5476.
https://doi.org/10.1182/blood-2023-179255
Published: 2023
Journal Articles

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Margaret V. Ragni, Scott Rothenberger, Robert Feldman, Danielle Nance, Andrew D Leavitt, Lynn Malec, Robert F. Sidonio, Jr., Eric H. Kraut, Joseph L Lasky, III, Claire S. Philipp, Dana E. Angelini, Rajiv K. Pruthi, Nina Hwang, Allison P. Wheeler, Roshni Kulkarni, Craig D. Seaman, Frederico Xavier, Nicoletta C Machin, Michael Meyer, Daniel Bellissimo, Kenneth J. Smith, Elizabeth P. Merricks, Timothy C. Nichols, Dana Ivanco, Deborah Vehec, Glory Koerbel, Andrew D. Althouse
Journal: Blood
Blood (2022) 140 (Supplement 1): 1413–1415.
https://doi.org/10.1182/blood-2022-156921
Published: 2022
Journal Articles

Patterns of Direct Oral Anticoagulant Use in Pediatric Patients: Results from a Multicenter National Database

Meghan McCormick, Molly Mack, Frederico Xavier
Journal: Blood
Blood (2022) 140 (Supplement 1): 5673–5674.
https://doi.org/10.1182/blood-2022-169638
Published: 2022
Journal Articles

Continuous Low-Dose Heparin Infusion for Catheter-Related Thrombosis Prophylaxis in Critically-Ill Children

Kenneth E. Bujold, III, DO,MS, Eric Scott Halstead, MD PhD, Frederico Xavier, MD MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-133914
Published: 2020
Journal Articles

Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Margaret V. Ragni, MD MPH, Frederico Xavier, MD MS, Craig D. Seaman, Suchitra Acharya, MD, Catherine E. McGuinn, MD, Eric J. Werner, MD, Courtney Elizabeth Lawrence, MDMS, Allison P. Wheeler, MD, Ulrike Reiss, MD, Irmel Ayala, MD, Erin Cockrell, DO, Cristina Tarango, MD, Amy Dunn, Roshni Kulkarni, MD, Sanjay P Ahuja, MD, Meera B. Chitlur, MD, Steven W. Pipe, MD, Lynn M Malec, MD, Vilmarie Rodriguez, MD, Shelley Crary, MD MS, Deborah Brown, MD, Rosa Diaz, MD, Maria Velez, MD, Cindy A. Leissinger, MD, Shannon L Carpenter, MD, Christine M. Knoll, MD, Michael Wang, MD, Guy Young, MD, Courtney D Thornburg, MD, Joseph L Lasky, III, MD, Tiffany Lin Lucas, MD, Nina Hwang, MD, Deborah Vehec, MSN, RN, Dana Ivanco, Tamara L. Haller, BS, Marnie Bertolet, PhD, Maria M Brooks, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-136814
Published: 2020
Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 2416.
https://doi.org/10.1182/blood-2019-123198
Published: 2019
Journal Articles

Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

Patrick T. Ebbert, BS, Margaret V. Ragni, MD MPH, Frederico Xavier, MD MS, Lynn M. Malec, MD, Craig D. Seaman
Journal: Blood
Blood (2017) 130 (Supplement 1): 3689.
https://doi.org/10.1182/blood.V130.Suppl_1.3689.3689
Published: 2017